Shaila Gogate, MD
Allergy & Immunology · Denver, CONPI 1629124235
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,588 of the $20,671 with a category attached, or 80.2%. Novartis accounts for 89.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $13,664 and has fallen 97.5% since, to $346 in 2025.
Across 144 payments — averaging $143.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$18K
- Genentech USA, Inc.$410
- GSK$373
- Sanofi$276
- AstraZeneca$254
- Pfizer$213
- plus $742 from 17 others
Across 434 payments — averaging $9245.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.1M
- Novartis$1.1M
- Teva Pharmaceuticals USA, Inc.$454K
- Cipla USA Inc.$260K
- Hikma Pharmaceuticals USA$232K
- GSK$228K
- plus $599K from 8 others
What the payments were for
- Consulting fees$16,58880%
- Travel & lodging$1,4277%
- Food & beverage$2,62113%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $18,402 |
| Genentech USA, Inc. | 29 | $410 |
| GSK | 22 | $373 |
| Sanofi | 11 | $276 |
| AstraZeneca | 14 | $254 |
| Pfizer | 10 | $213 |
| Regeneron Healthcare Solutions, Inc. | 7 | $126 |
| AbbVie | 3 | $73 |
| Kaleo, Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Biocryst US Sales Co., LLC | 3 | $58 |
| Blueprint Medicines Corporation | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| CSL Behring | 2 | $44 |
| Optinose US, Inc. | 2 | $40 |
| Lilly USA, LLC | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Pharming Healthcare, Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
How this compares
$20,671 in reported general payments places this provider in the 80th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $29,591 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $24,416 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $13,332 |
| Spiriva RespimatTiotropium Bromide | 21 | $12,376 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $6,834 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,307 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $4,439 |
| Ipratropium Bromide | 102 | $4,094 |
| Epinephrine | 12 | $2,806 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $1,761 |
| Montelukast Sodium | 55 | $943 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $767 |
| Azelastine Hcl | 15 | $418 |
| Levocetirizine Dihydrochloride | 21 | $216 |
| Prednisone | 20 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $373 | $34,89842 claims |
| AstraZenecaSymbicort | $254 | $24,41666 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $49 | $4,43917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Denver
- Rohit KatialDenver$758K
- Eileen WangDenver$274K
- Donald LeungDenver$208K
- Flavia HoyteDenver$70K
- Bruce LanserDenver$34K
- Harold NelsonDenver$14K
- Anna MeyerDenver$9K
- Monica ReddyDenver$6K
- Jessica HuiDenver$5K
- Ronina CovarDenver$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.